A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
David C. Jackson(The University of Melbourne), Lorena E. Brown(Hokkaido University of Science), Christina Cheers(The University of Melbourne), Andreas Suhrbier(The University of Queensland), Weiguang Zeng(The University of Melbourne), Georgia Deliyannis(The University of Melbourne), Thuy T. Le(The University of Melbourne), Yuk Fai Lau(The University of Melbourne), Corey Smith(QIMR Berghofer Medical Research Institute)
Cited by 235
Related Papers
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies
|Clinical Microbiology Reviews|2017|226